Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Theramex to Exclusively License Intrarosa® In Europe, Australia, Russia and The Ukraine from Endoceutics

Theramex
Posted on: 19 Jul 18
  •    Intrarosa® is an innovative treatment for vulvovaginal atrophy in post-menopausal women
  •    Strengthens Theramex’s position as a leader in Women’s Health

 

London, UK and Quebec City, Canada, July 19th, 2018; Today, Theramex and Endoceutics announced they have entered into a definitive agreement granting Theramex the license to commercialise Intrarosa® (Prasterone) across countries in Europe, Australia, Russia as well as select countries within the Commonwealth of Independent States (CIS). Intrarosa is a unique non-estrogen prescription therapy approved for the treatment of vulvar and vaginal atrophy (VVA) in postmenopausal women experiencing moderate to severe symptoms.1 VVA can lead to dryness, irritation and dyspareunia (or pain during sexual activity).

Anish Mehta, Chief Executive Officer at Theramex said "Intrarosa is a novel medicine that offers an effective treatment for a very common condition in postmenopausal women.  We are pleased to be able to continue the ground-breaking work of Dr Fernand Labrie, the founder and Chief Executive Officer of Endoceutics. With our strong heritage and commitment to Women’s Health, we are looking forward to making Intrarosa available to women to better address this condition."

"Intrarosa is an excellent addition to our portfolio of products that help women manage the symptoms of menopause. This deal is an example of our commitment to become the leading healthcare company dedicated to Women’s Health", added Anish Mehta.

Dr Fernand Labrie, founder and Chief Executive Officer of Endoceutics said "As a non-estrogen treatment, Intrarosa is a novel vaginal prescription therapy that locally replaces inside the cells what is missing for patients with vulvovaginal atrophy. Intrarosa improves the body's natural ability to produce hormones locally and intracellularly, thus correcting the symptoms, such as pain during sexual activity, without influencing other tissues. Since Intrarosa is not an estrogen-based product, patients should feel more comfortable seeking a treatment in line with physiology and all circulating steroids remaining within normal values."

Dr Labrie also added "I’m pleased to be working closely with Theramex, a company that shares our vision of helping women live better, symptom-free lives.  I believe their expertise and knowledge of the Women’s Health community will make Intrarosa accessible to women across countries including those in Europe, Russia and Australia who presently struggle to find effective solutions for these very intimate, and yet very common, symptoms of menopause.”

VVA is a common condition affecting up to 50% of postmenopausal women2,3. In women with VVA, the wall of the vagina and surrounding tissues become thinner and cause symptoms such as dryness, irritation and soreness around the genital area and pain at sexual activity (also called dyspareunia). In clinical trials, Intrarosa was shown to improve the structure of the vaginal tissues and reduce pain during sexual intercourse. In the clinical trials, Intrarosa was well tolerated.1,4,5

While the deal terms have not been disclosed, countries within the license agreement are: Australia, Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Liechtenstein, Lithuania, Luxembourg, Malta, Netherlands, Poland, Romania, Serbia, Slovakia, Slovenia, United Kingdom, the Russian Federation, Kazakhstan, and the Ukraine. Intrarosa was first approved by the US Food and Drug Administration in November 2016 for the treatment of moderate to severe dyspareunia, a symptom of VVA due to menopause5 and by the European Medicines Agency in January 2018 for the treatment of VVA.

Editor's Details

Mike Wood
PharmiWeb.com
www.pharmiweb.com
editor@pharmiweb.com

Last updated on: 19/07/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.